01:54 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
20:28 , Feb 6, 2019 |  BC Extra  |  Company News

Management tracks: Astellas, Blueprint

Astellas Pharma Inc. (Tokyo:4503) said President of Pharmaceutical Technology Mitsunori Matsuda and President of Asia & Oceania Business Masatoshi Kuroda will resign, effective June 18. Hideki Shima will succeed Matsuda. Cancer and rare diseases company...
17:51 , Feb 6, 2019 |  BC Extra  |  Company News

FDA approves Sanofi's Cablivi for rare clotting disease

Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:57 , Jan 17, 2019 |  BC Week In Review  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
23:26 , Jan 15, 2019 |  BC Extra  |  Company News

Sanofi expands multitargeting toolbox with Biomunex deal

Sanofi (Euronext:SAN; NASDAQ:SNY) has expanded its toolbox for developing multispecific modalities through a licensing deal with Biomunex Pharmaceuticals (Paris, France). The deal gives Sanofi access to Biomunex's Plug-and-Play BiXAb platform, which generates bi-specific and multispecific...
22:48 , Dec 20, 2018 |  BC Extra  |  Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

Exosome therapy company Evox Therapeutics Ltd. (Oxford, U.K.) appointed Edwin Moses as chairman. This month, the former Ablynx N.V. CEO was also appointed chairman of Virion Biotherapeutics Ltd. (London, U.K.) and Achilles Therapeutics Ltd. (Stevenage,...
22:09 , Dec 17, 2018 |  BC Extra  |  Company News

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral gene therapy company Generation Bio Co. (Cambridge, Mass.). Ian Smith, Vertex EVP and COO and former CFO,...
00:39 , Dec 11, 2018 |  BC Extra  |  Company News

Management tracks: Grail, EUSA

Cancer detection company Grail Inc. (Menlo Park, Calif.) appointed Catherine Friedman chairman. She succeeds Bill Rastetter, who will continue as a director. Friedman joined Grail's board last year and also serves on the board of...
18:30 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Sept. 3 that FDA accepted and granted Priority Review to...